Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

Clinical trial NCT06692712 · RECRUITING

Trial details

NCT number: NCT06692712
Sponsor: Elpida Therapeutics SPC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hereditary Spastic Paraplegia Type 50

Start date: 2026-04-01
Primary completion: 2032-02-28
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.